To hear about similar clinical trials, please enter your email below
Trial Title:
Myosteatosis in Oeso-gastric Cancer: Clinical Impacts
NCT ID:
NCT06419244
Condition:
Esophageal Cancer
Gastric Cancer
Myopenia
Adipose Tissue Tumor
Conditions: Official terms:
Stomach Neoplasms
Neoplasms, Adipose Tissue
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Basic Science
Masking:
None (Open Label)
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Myosteatosis
Description:
Determination of myosteatosis by imaging
Arm group label:
Non surgical patients
Arm group label:
Surgical patients
Summary:
The aim of this project is to study the presence of cancer-associated adipocytes in
oesogastric cancers and their possible links with myosteatosis. This research project has
a retrospective component, the aim of which is to analyse the body component based on
imaging in patients with oesogastric neoplasia in order to determine the incidence of
myosteatosis and to study the relationship with oncological and prognostic data. The
second part of the project is prospective and will collect biological material (skeletal
muscle, adipose tissue, tumour, blood) for histological, molecular and genomic analyses
and will analyse muscle function in patients with oesogastric cancer. It will address the
role of adipocytes in the tumour microenvironment of oesogastric cancer, focusing on
their interactions with the observed muscle myosteatosis and prognosis. In the future, it
will help to identify signalling pathways, targets and patients who could benefit from
appropriate treatment.
Detailed description:
Oesophageal and gastric cancer pose a significant challenge to caregivers, both in terms
of the complexity of its presentation and its treatment. At diagnosis, patients often
present with malnutrition associated with sarcopenia, which has a significant impact on
morbidity and mortality. Although loss of muscle mass has received much attention in
cancer, muscle quality, particularly the accumulation of fat in muscle named
"myosteatosis", may be considered as a better predictor of a patient's physical condition
and ability to recover from cancer treatments. Studying the tumor microenvironment is
essential to understanding the mechanisms underlying disease progression.
Cancer-associated adipocytes (CAA), a major component of this tumor microenvironment,
provide an interface for dialogue with the tumor through the secretion of
pro-inflammatory cytokines, metalloproteases and the release of free fatty acids. They
have been described as capable of stimulating tumor progression, particularly in breast
cancer. However, their presence in oesogastric cancer and possible links with
myosteatosis have not been described.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patients with cancer of the oesophagus, oeso-gastric junction or stomach
- Treatment and estimated survival of more than 3 months
- Signed informed consent
- > 18 years of age
Exclusion Criteria:
- Neuromuscular or orthopedic pathology
- Cognitive disorders
- Psychiatric disorders
- Inability to communicate in French or English
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Cliniques universitaires Saint-Luc
Address:
City:
Bruxelles
Zip:
1200
Country:
Belgium
Status:
Recruiting
Contact:
Last name:
Yannick Deswysen, MD
Phone:
00327642213
Email:
yannick.deswysen@saintluc.uclouvain.be
Start date:
May 1, 2024
Completion date:
May 31, 2026
Lead sponsor:
Agency:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Agency class:
Other
Source:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06419244
